Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

Diffuse large B cell lymphoma (DLBCL) is successfully treated with combination immuno-chemotherapy, but relapse with resistant disease occurs in ~ 40% of patients. However, little is known regarding relapsed/refractory DLBCL (rrDLBCL) genetics and alternative therapies. Based on findings from other...

Descripción completa

Detalles Bibliográficos
Autores principales: Benoit, Alexandre, Bou-Petit, Elisabeth, Chou, Hsiang, Lu, Melissa, Guilbert, Cynthia, Luo, Vincent Mingyi, Assouline, Sarit, Morin, Ryan D., Dmitrienko, Svetlana, Estrada-Tejedor, Roger, Johnson, Nathalie A., Mann, Koren K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764096/
https://www.ncbi.nlm.nih.gov/pubmed/35039569
http://dx.doi.org/10.1038/s41598-021-04736-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764096/
https://www.ncbi.nlm.nih.gov/pubmed/35039569
http://dx.doi.org/10.1038/s41598-021-04736-0

Ejemplares similares